1
Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)
Condition(s):Proliferative VitreoretinopathyLast Updated:September 17, 2021Recruiting
Adrenocorticotropic Hormone: 477 Clinical Trials, Page 1 of 48
Hide Studies Not Open or Pending
2
Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses
Condition(s):Multiple SclerosisLast Updated:January 19, 2017Unknown status
3
Acthar SLE (Systemic Lupus Erythematosus)
Condition(s):Systemic Lupus Erythematosus (SLE); Repository Corticotropin InjectionLast Updated:September 13, 2019Withdrawn
4
Use of CXCL9 as a Biomarker of Acthar Efficacy
Condition(s):SarcoidosisLast Updated:March 24, 2020Not yet recruiting
5
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Condition(s):Dermatomyositis; Juvenile DermatomyositisLast Updated:September 16, 2021Completed
6
ACTH Gel Therapy in Rheumatoid Arthritis
Condition(s):Rheumatoid ArthritisLast Updated:August 10, 2021Recruiting
7
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
Condition(s):UveitisLast Updated:September 27, 2018Unknown status
8
Adrenocorticotropic Hormone in Membranous Nephropathy
Condition(s):Membranous NephropathyLast Updated:March 18, 2021Completed
9
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Condition(s):Dermatomyositis; PolymyositisLast Updated:September 1, 2017Completed
10
Acthar on Proteinuria in IgA Nephropathy Patients
Condition(s):IgA Nephropathy; ProteinuriaLast Updated:April 5, 2017Withdrawn